Changzhou Qianhong Biopharma CO.,LTD

SZSE:002550 Rapport sur les actions

Capitalisation boursière : CN¥7.0b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Changzhou Qianhong BiopharmaLTD Croissance future

Future contrôle des critères 4/6

Changzhou Qianhong BiopharmaLTD is forecast to grow earnings and revenue by 25.9% and 16% per annum respectively. EPS is expected to grow by 25.8% per annum. Return on equity is forecast to be 14.3% in 3 years.

Informations clés

25.9%

Taux de croissance des bénéfices

25.8%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices18.8%
Taux de croissance des recettes16.0%
Rendement futur des capitaux propres14.3%
Couverture par les analystes

Low

Dernière mise à jour17 Aug 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Changzhou Qianhong BiopharmaLTD (SZSE:002550) Has Affirmed Its Dividend Of CN¥0.12

May 26
Changzhou Qianhong BiopharmaLTD (SZSE:002550) Has Affirmed Its Dividend Of CN¥0.12

Changzhou Qianhong Biopharma CO.,LTD (SZSE:002550) Looks Just Right With A 26% Price Jump

May 21
Changzhou Qianhong Biopharma CO.,LTD (SZSE:002550) Looks Just Right With A 26% Price Jump

Investors Can Find Comfort In Changzhou Qianhong BiopharmaLTD's (SZSE:002550) Earnings Quality

May 02
Investors Can Find Comfort In Changzhou Qianhong BiopharmaLTD's (SZSE:002550) Earnings Quality

Does Changzhou Qianhong BiopharmaLTD (SZSE:002550) Have A Healthy Balance Sheet?

Mar 24
Does Changzhou Qianhong BiopharmaLTD (SZSE:002550) Have A Healthy Balance Sheet?

Prévisions de croissance des bénéfices et des revenus

SZSE:002550 - Estimations futures des analystes et données financières antérieures (CNY Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20262,562438N/A4643
12/31/20252,175362N/A2113
12/31/20241,831303N/A4203
3/31/20241,667200638733N/A
12/31/20231,814182433533N/A
9/30/20232,121253294374N/A
6/30/20232,223241-1856N/A
3/31/20232,360281-261-192N/A
1/1/20232,304323-142-71N/A
9/30/20222,155260-4142N/A
6/30/20222,13929437120N/A
3/31/20222,036255208291N/A
1/1/20221,87518113104N/A
9/30/20211,873-8823103N/A
6/30/20211,886-107153231N/A
3/31/20211,913-52160233N/A
12/31/20201,668-132255317N/A
9/30/20201,694188154246N/A
6/30/20201,48715158155N/A
3/31/20201,454148-3370N/A
12/31/20191,67526361162N/A
9/30/20191,46223281196N/A
6/30/20191,49023325137N/A
3/31/20191,350227-799N/A
12/31/20181,322221-7825N/A
9/30/20181,312222-85-35N/A
6/30/20181,223202-836N/A
3/31/20181,1601974590N/A
12/31/20171,065183N/A91N/A
9/30/2017995212N/A123N/A
6/30/2017931226N/A61N/A
3/31/2017863225N/A148N/A
12/31/2016776224N/A221N/A
9/30/2016773250N/A205N/A
6/30/2016788277N/A272N/A
3/31/2016750277N/A292N/A
12/31/2015757267N/A287N/A
9/30/2015730268N/A301N/A
6/30/2015744270N/A292N/A
3/31/2015771259N/A277N/A
12/31/2014815245N/A252N/A
9/30/2014807226N/A240N/A
6/30/2014791205N/A194N/A
3/31/2014832191N/A150N/A
12/31/2013861187N/A160N/A
9/30/2013907188N/A209N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 002550's forecast earnings growth (25.9% per year) is above the savings rate (2.9%).

Bénéfices vs marché: 002550's earnings (25.9% per year) are forecast to grow faster than the CN market (21.9% per year).

Croissance élevée des bénéfices: 002550's earnings are expected to grow significantly over the next 3 years.

Chiffre d'affaires vs marché: 002550's revenue (16% per year) is forecast to grow faster than the CN market (13.4% per year).

Croissance élevée des revenus: 002550's revenue (16% per year) is forecast to grow slower than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: 002550's Return on Equity is forecast to be low in 3 years time (14.3%).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y